In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to BioNano Genomics (BNGO), with a price target of $14.00. The company’s shares closed last Wednesday at $11.85, close to its 52-week high of $13.85.
According to TipRanks.com, McCarthy is a top 25 analyst with an average return of 64.3% and a 65.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
Currently, the analyst consensus on BioNano Genomics is a Strong Buy with an average price target of $7.56, which is a -36.5% downside from current levels. In a report issued on January 26, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $14.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.85 and a one-year low of $0.25. Currently, BioNano Genomics has an average volume of 76.65M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.